South Africa – Boehringer Ingelheim South Africa announced today that it has granted a voluntary license to the South African pharmaceutical manufacturer Aspen Pharmacare for the production, distribution and sale of the antiretroviral nevirapine (marketed world wide by Boehringer Ingelheim as VIRAMUNE). It is the first time that Boehringer Ingelheim has granted a non-exclusive voluntary… Continue reading Boehringer Ingelheim grants a voluntary license for nevirapine to South African company Aspen Pharmacare
Aspen is in a closed period from 1st July 2024 until the publication of the FY2024 results on the JSE SENS platform to be released on the 3rd September 2024.
